We are live on
!
Find out more
GIM
Granahan Investment Management Portfolio holdings
AUM
$2.07B
1-Year Est. Return
56.45%
This Fund
S&P 500
This Quarter
Est. Return
+53.18%
1 Year Est. Return
+56.45%
3 Year Est. Return
+154.74%
5 Year Est. Return
+144.99%
10 Year Est. Return
+2,522.93%
AUM
$4.46B
AUM Growth
+$1.51B
(+51%)
Cap. Flow
+$324M
Cap. Flow
% of AUM
7.28%
Top 10 Holdings %
Top 10 Hldgs %
35.21%
Holding
208
New
28
Increased
93
Reduced
71
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Workiva
WK
|
+$52.1M |
| 2 |
Kulicke & Soffa
KLIC
|
+$40.4M |
| 3 |
DMYD
dMY Technology Group, Inc. II
DMYD
|
+$39.8M |
| 4 |
MSP
Datto Holding Corp.
MSP
|
+$35.7M |
| 5 |
VIEW
View, Inc. Class A Common Stock
VIEW
|
+$29.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Magnite
MGNI
|
+$50.1M |
| 2 |
Trade Desk
TTD
|
+$41.3M |
| 3 |
PS
Pluralsight, Inc. Class A Common Stock
PS
|
+$33.7M |
| 4 |
Paylocity
PCTY
|
+$31M |
| 5 |
Sonic Automotive
SAH
|
+$25.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 38.6% |
| 2 | Healthcare | 16.36% |
| 3 | Industrials | 13.09% |
| 4 | Consumer Discretionary | 9.99% |
| 5 | Communication Services | 5.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
CRISPR Therapeutics
CRSP
$5.16B
| $8.76M | 0.2% |
57,197
+17,863
| +45% | +$2.11M |
|
102
Casella Waste Systems
CWST
$5.85B
| $8.48M | 0.19% |
136,889
+4,042
| +3% | +$240K |
|
103
Spero Therapeutics
SPRO
$70.6M
| $8.15M | 0.18% |
420,320
+46,242
| +12% | +$721K |
|
104
Karyopharm Therapeutics
KPTI
$46.2M
| $7.78M | 0.17% |
33,503
+15,657
| +88% | +$3.63M |
|
105
BioLife Solutions
BLFS
$1.7B
| $7.75M | 0.17% |
194,163
-43,920
| -18% | -$1.5M |
|
106
Xencor
XNCR
$1.63B
| $7.65M | 0.17% |
175,429
+104,298
| +147% | +$4.31M |
|
|
VG
107
DELISTED
Vonage Holdings Corporation
VG
| $7.59M | 0.17% |
589,342
-276,125
| -32% | -$3.36M |
|
|
XLRN
108
DELISTED
Acceleron Pharma
XLRN
| $7.48M | 0.17% |
58,474
-58,022
| -50% | -$6.8M |
|
109
Gray Television
GTN
$497M
| $7.31M | 0.16% |
408,589
-88,318
| -18% | -$1.4M |
|
110
Rapid7
RPD
$935M
| $7.12M | 0.16% |
78,959
-5,097
| -6% | -$365K |
|
111
Power Integrations
POWI
$3.52B
| $6.7M | 0.15% |
81,780
+20,557
| +34% | +$1.39M |
|
112
Intellia Therapeutics
NTLA
$1.67B
| $6.64M | 0.15% |
122,143
+48,109
| +65% | +$1.75M |
|
113
MacroGenics
MGNX
$252M
| $6.63M | 0.15% |
289,861
+105,986
| +58% | +$2.44M |
|
|
114
Trade Desk
TTD
$6.37B
| $6.61M | 0.15% |
82,470
-547,280
| -87% | -$41.3M |
|
115
SI-BONE Inc
SIBN
$849M
| $6.56M | 0.15% |
+219,327
| New | +$5.34M |
|
116
Harvard Bioscience
HBIO
$27.3M
| $6.54M | 0.15% |
152,335
-23,383
| -13% | -$873K |
|
|
SHSP
117
DELISTED
SharpSpring, Inc.
SHSP
| $6.49M | 0.15% |
398,701
+186,590
| +88% | +$2.6M |
|
118
Cytosorbents Corp
CTSO
$22.6M
| $6.44M | 0.14% |
807,699
+175,664
| +28% | +$1.47M |
|
119
Vicor
VICR
$9.77B
| $6.05M | 0.14% |
65,560
+21,789
| +50% | +$1.83M |
|
120
Airgain
AIRG
$71.4M
| $5.96M | 0.13% |
335,105
+44,033
| +15% | +$613K |
|
|
NPTN
121
DELISTED
NEOPHOTONICS CORP
NPTN
| $5.82M | 0.13% |
640,481
+329,341
| +106% | +$2.55M |
|
|
SMED
122
DELISTED
Sharps Compliance Corp
SMED
| $5.78M | 0.13% |
611,968
+265,228
| +76% | +$2.03M |
|
|
P
123
Everpure Inc
P
$34.4B
| $5.75M | 0.13% |
254,237
-159,110
| -38% | -$3.05M |
|
|
PRFT
124
DELISTED
Perficient Inc
PRFT
| $5.5M | 0.12% |
115,522
+1,116
| +1% | +$50.6K |
|
125
BGC Group
BGC
$4.83B
| $5.48M | 0.12% |
1,369,277
+324,048
| +31% | +$1.13M |
|
Similar funds
BC
AG
TA
ACP
TP
NSUP
ACG
CL
Granahan Investment Management's Q4 2020 Portfolio in Review
As of Q4 2020, Granahan Investment Management held 208 positions worth $4.46B, up 51% from $2.95B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Granahan Investment Management deployed $324M of net new capital in Q4 2020, opening 28 new positions and adding to 93 existing holdings. Its largest new stake was dMY Technology Group, Inc. II: 3,436,892 shares worth $60.5M.
By sector, the portfolio is most concentrated in Technology at 39% of assets, up from 35% a quarter earlier, followed by Healthcare and Industrials.
On the sell side, the largest reduction was Magnite, an estimated $50.1M trimmed.
- Granahan Investment Management's largest Q4 2020 buy was dMY Technology Group, Inc. II: 3,436,892 shares worth $60.5M.
- Granahan Investment Management added most to Workiva in Q4 2020, an estimated $52.1M increase.
- Granahan Investment Management's biggest Q4 2020 reduction was Magnite, cutting an estimated $50.1M.
- Granahan Investment Management fully exited Pluralsight, Inc. Class A Common Stock in Q4 2020, selling an estimated $33.7M.
- Granahan Investment Management's ten largest holdings make up 35% of its $4.46B portfolio in Q4 2020.
- Granahan Investment Management opened 28 new positions and closed 16 in Q4 2020.
- Granahan Investment Management's portfolio value rose 51% quarter-over-quarter to $4.46B.
Based on Granahan Investment Management's 13F filing for Q4 2020, filed 12 Feb 2021.